Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-year, Randomized, Double-blind, Placebo-controlled, Multi-center, Phase II-III Study to Evaluate the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy

NCT00927914 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00927914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00927914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-year, Randomized, Double-blind, Placebo-controlled, Multi-center, Phase II-III Study to Evaluate the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy
Lead sponsor
Eisai Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
July 31, 2009
Completion date
February 28, 2013
Enrollment
800 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mild to moderate diabetic sensorimotor polyneuropathy